首页> 外国专利> for the smooth muscle of arteries and veins of the smooth muscle specific proteins and their use

for the smooth muscle of arteries and veins of the smooth muscle specific proteins and their use

机译:用于动脉和静脉的平滑肌的平滑肌特异蛋白及其用途

摘要

Arterial and venous smooth muscle cells are molecularly distinct from the earliest stages of angiogenesis through to adulthood. This distinction is revealed by expression on arterial cells (e.g., arterial endothelial cells, arterial smooth muscle cells) of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous cells are necessary for angiogenesis. Expression of EphrinB2 in arterial cells (e.g., arterial endothelial cells, arterial smooth muscle cells) can be used to advantage in methods for targeting agents and/or encoded polypeptides to arterial smooth muscle cells, altering angiogenesis, assessing the effect of agents on arterial smooth muscle cells, identifying arterial smooth muscle cells, isolating arterial smooth muscle cells and production of artificial vessels, for example.
机译:从血管生成的最早阶段到成年,动脉和静脉平滑肌细胞在分子上是不同的。这种区别通过称为EphrinB2的跨膜配体在动脉细胞(例如,动脉内皮细胞,动脉平滑肌细胞)上的表达而揭示,其受体EphB4在静脉细胞上表达。 EphrinB2基因的靶向破坏可防止静脉从毛细血管丛重塑成适当分支的结构。此外,它还破坏了动脉的重塑,表明预先指定的动脉和静脉细胞之间的相互作用是血管生成所必需的。 EphrinB2在动脉细胞(例如,动脉内皮细胞,动脉平滑肌细胞)中的表达可用于将试剂和/或编码的多肽靶向动脉平滑肌细胞,改变血管生成,评估试剂对动脉平滑肌的作用的方法肌肉细胞,识别动脉平滑肌细胞,分离动脉平滑肌细胞和生产人造血管。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号